Stay updated on Comparing 15 vs 30 mg CVL-231 in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Comparing 15 vs 30 mg CVL-231 in Schizophrenia Clinical Trial page.

Latest updates to the Comparing 15 vs 30 mg CVL-231 in Schizophrenia Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check46 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check67 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check75 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check96 days agoChange DetectedNew entries have been added, including a completed status and several important dates related to Julie Adams at AbbVie, while previous entries related to Erica Koenig at Cerevel Therapeutics have been removed.SummaryDifference1%
Stay in the know with updates to Comparing 15 vs 30 mg CVL-231 in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing 15 vs 30 mg CVL-231 in Schizophrenia Clinical Trial page.